INOVIQ Ltd
IIQ.AX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$19M
Close$
$-0.06
143.5% downside
Current Fair Value
143.5% downsideOvervalued by 143.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $19.00 Million |
|---|---|
| Enterprise Value | $9.94 Million |
| Earnings per Share | $-0.06 |
| Beta | 1.48 |
| Outstanding Shares | 140,775,458 |
Return
| Return on Equity | -76.42% |
|---|---|
| Return on Assets | -70.59% |
| Return on Invested Capital | -88.61% |
Valuation & Multiples
| P/E Ratio | -2.36 |
|---|---|
| PEG | -28.81 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.42 |
| Enterprise Value to EBIT | -0.58 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$202,463
Consensus analyst estimateNext Earnings Call
Expected Date
February 19, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$226,828
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About INOVIQ Ltd
15 employees
CEO: Leearne Maree Hinch
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its...